CCM-205 / CCM Bio - LARVOL DELTA

Novel potent and selective fourth-generation inhibitors targeting EGFR for NSCLC therapy. (ASCO 2025) - " We have characterized the efficacy of two novel fourth-generation EGFR inhibitors, CCM-205 and CCM-308, which are potent against both mutational and non-mutational tumor resistance to Osimertinib. Novel fourth-generation EGFR inhibitors have been developed that can potentially overcome both on-target and off-target resistance in NSCLC and have potential clinical applications."

Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR

CCM Biosciences Announces Presentation of Data on its First-In-Class NSCLC Drug Program at ASCO 2025 (Businesswire) - "At ASCO 2025, CCM Biosciences’ presentation 'Novel, potent and selective fourth-generation inhibitors targeting EGFR for NSCLC therapy' in the Lung Cancer – Non-small cell – Metastatic session (Abstract #: 8622, https://www.asco.org/abstracts-presentations/ABSTRACT495872) will report novel 4th-generation, orally bioavailable EGFR inhibitors (CCM-205, CCM-245 and CCM-308) that can overcome both on-target and off-target resistance in lung cancer models, significantly outperforming the aforementioned 4th-generation inhibitors in the face of resistance to 3rd-generation inhibitors, and have significant potential clinical applications....CCM Biosciences is advancing clinical candidates from its EGFR inhibitor program to investigational new drug (IND) filing this year for entry to clinical trials."

IND • Preclinical • Non Small Cell Lung Cancer